Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-20-064425
Filing Date
2020-12-18
Accepted
2020-12-18 16:29:06
Documents
1
Period of Report
2020-12-17

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 23579
  Complete submission text file 0001209191-20-064425.txt   24966
Mailing Address C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Business Address
KARSEN PERRY A (Reporting) CIK: 0001260573 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37766 | Film No.: 201400962

Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances